Press Releases

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Aug 20, 2021
2021
Press Release Non-regulatory

Interim Report Elicera Therapeutics AB January – June 2021

Read more
Jul 5, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market

Read more
Jul 5, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics' board and management buy shares

Read more
Jun 24, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus

Read more
Jun 10, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market

Read more
Jun 9, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics' new issue heavily oversubscribed

Read more
Jun 4, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market

Read more
May 24, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market

Read more
Apr 27, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses

Read more
Apr 15, 2021
2021
Press Release Non-regulatory

Biostock writes about Elicera and CAR T-cells

Read more
Mar 22, 2021
2021
Press Release Non-regulatory

Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board

Read more
Jan 11, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics recruits CFO

Read more
Jan 8, 2021
2021
Press Release Non-regulatory

Elicera Therapeutics invitation to company presentation (in Swedish)

Read more
Oct 5, 2020
2020
Press Release Non-regulatory

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Read more
Apr 23, 2020
2020
Press Release Non-regulatory

Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

Read more

Sign up for Press Releases

By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.